Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-associated membrane antigens (TAMAs) are cell-surface proteins or glycoproteins that are upregulated or aberrantly expressed on cancer cells. They serve as targets for immune surveillance and therapeutic intervention. TAMAs can be used as diagnostic markers and targeted by monoclonal antibodies, antibody-drug conjugates (ADCs), and CAR-T cell therapy. However, immune tolerance and suppression within the tumor microenvironment can limit the efficacy of TAMA-targeted therapies.
Antibody-dependent cellular cytotoxicity (ADCC), complement activation, phagocytosis enhancement, direct interference with essential signaling pathways required for tumor growth/survival
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor-associated membrane antigen (TAMA).